Future trends in antimicrobial chemotherapy:: Expert opinion on the 43rd ICAAC

被引：15

作者：

Ball, AP

Bartlett, JG

Craig, WA

Drusano, GL

Felmingham, D

Garau, JA

Klugman, KP

Low, DE

Mandell, LA

Rubinstein, E

Tillotson, GS

机构：

[1] Univ St Andrews, St Andrews KY16 9AJ, Fife, Scotland

[2] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA

[3] Univ Wisconsin, Sch Med, Dept Med, Clin Pharmacol Sect, Madison, WI USA

[4] Ordway Res Inst, Albany, NY USA

[5] GR Micro Ltd, London, England

[6] Univ Barcelona, E-08007 Barcelona, Spain

[7] Emory Univ, Sch Med, Dept Int Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA

[8] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA

[9] Toronto Med Labs, Dept Microbiol, Toronto, ON, Canada

[10] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada

[11] Univ Toronto, Toronto, ON, Canada

[12] McMaster Univ, Dept Med, Hamilton, ON, Canada

[13] Tel Aviv Univ, Sch Med, Fac Med, IL-69978 Tel Aviv, Israel

[14] Oscient Pharmaceut, Walton, MA USA

来源：

JOURNAL OF CHEMOTHERAPY | 2004年 / 16卷 / 05期

关键词：

appropriate use; immunomodulation; antimicrobial resistance; fluoroquinolones; macrolides; ketolides; beta-lactams; oxazolidinones; clinical trials;

D O I：

10.1179/joc.2004.16.5.419

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The current document bestows an expert synopsis of key new information presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in 2003. Data is presented on the socio-political aspects of and policies on antimicrobial prescribing, novel mechanisms of resistance in Streptococcus pneumoniae, and current epidemiological trends in global resistance. Novel information on new (and existing) antimicrobial agents-new penicillins, cephalosporins, monobactams and oxipenem inhibitors, ketolides, glycopeptides, fluoroquinolones (and hybrids), peptides, daptomycin, aminomethylcyclines, glycylcyclines, and newer formulations of agents such as amoxycillin-clavulanate provides renewed hope that resistant pathogens can be controlled through use of more potent agents. Improved strategies for the use of existing antimicrobial agents, such as the use of high-dose regimens, short-course therapy, also may delay or reduce the development of resistance and preserve the value of our antibiotic armamentarium.

引用

页码：419 / 436

页数：18

共 156 条

[1]

Abena PA, 2001, JAMA-J AM MED ASSOC, V286, P1973, DOI 10.1001/jama.286.16.1973

[2] Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae [J].